Last updated: March 27, 2024
Sponsor: The First Hospital of Hebei Medical University
Overall Status: Active - Recruiting
Phase
1/2
Condition
Memory Loss
Mild Cognitive Impairment
Blood Clots
Treatment
Pentoxifylline
Clinical Study ID
NCT06344390
20210327
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Han Chinese, age 40-80 years old, male and female, right-handed;
- The diagnosis is consistent with the Expert Consensus on the Management of CognitiveImpairment after Stroke 2021;
- NIHSS score 1-15 points;
- Daily Living Ability Scale (ADL) ≥75 score;
- The Informed consent signed by the patient or his legal representative
Exclusion
Exclusion Criteria:
- Can not cooperate with the examination (including neuropsychological tests and scaleassessment);
- There were memory disorders, dementia with lewy bodies and frontotemporal dementiabefore the onset of stroke events;
- There were definite infectious diseases 2 weeks before admission; Have a seriousmental illness, previous history of cancer, alcohol or drug abuse;
- Use of drugs that may affect cognitive function, including sedatives, anti-anxietydrugs, hypnotics, nootropic drugs, and cholinoid drugs;
- Can not accept brain MRI examination
Study Design
Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Pentoxifylline
Phase: 1/2
Study Start date:
April 10, 2024
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
BHan
Shijiazhuang,
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.